Dawood 1995.

Study characteristics
Methods	Trial design: Prospective, randomised, double‐blind study
Participants	Participants: 12 women were randomised and analysed. Mean age: The mean age was 29.4 ± 1.6 years for the LA group and 30.5 ± 2.9 years for the danazol group. Inclusion criteria: No use of specific hormone treatment or oral contraceptive use in the 6 months before enrolment in the study No previous use of GnRH analogue No surgical treatment was permitted at the time of pretreatment laparoscopy. Exclusion criteria:  Use of contraception other than the barrier method Setting: United states of America Timing: not stated
Interventions	Group 1: 3.7 mg leuprolide acetate monthly injection + oral placebo every day or  Group 2: 800 mg danazol orally + monthly placebo injection
Outcomes	Bone mineral density Hormone determinations
Notes	Intention‐to‐treat analysis: not stated Sample size calculation: not stated Funding: supported by a grant from TAP Pharmaceuticals, Inc., Deerfield, Illinois The author has not been reached for no working email address was available.
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	'randomized clinical trial' by randomisation code. No further details of method used to generate the randomisation sequence were provided.
Allocation concealment (selection bias)	Unclear risk	No further details of method used to conceal allocation were provided.
Blinding of participants and personnel (performance bias) All outcomes	Low risk	Blinding, placebo‐controlled study
Blinding of outcome assessment (detection bias) All outcomes	Low risk	Blinding, placebo‐controlled study
Incomplete outcome data (attrition bias) All outcomes	Low risk	No losses to follow‐up
Selective reporting (reporting bias)	Low risk	The study protocol was not available but it was clear that the published reports included all expected outcomes, including those that were prespecified.
Other bias	Low risk	No other risk of bias detected